4.7 Article

Impact of In-Hospital Major Bleeding on Late Clinical Outcomes After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 58, Issue 17, Pages 1750-1756

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2011.07.021

Keywords

bivalirudin; bleeding; clinical outcomes; prognosis

Funding

  1. Cardiovascular Research Foundation
  2. Boston Scientific
  3. Medicines Company
  4. Sanofi-Aventis
  5. Bristol-Myers Squibb
  6. Medtronic
  7. GlaxoSmithKline
  8. Eli Lilly-Daiichi Sankyo
  9. Merck
  10. AstraZeneca
  11. Abbott Vascular
  12. Bristol-Myers Squibb-Sanofi
  13. Abbott
  14. Adamed
  15. Biotronik
  16. Balton
  17. Bayer
  18. BBraun
  19. BioMatrix
  20. Boehringer Ingelheim
  21. Cordis
  22. Cook Eli Lilly
  23. EuroCor
  24. Glaxo
  25. Invatec
  26. MSD
  27. Nycomed
  28. Orbus-Neich
  29. Pfizer
  30. Possis
  31. Promed
  32. Siemens
  33. Solvay
  34. Terumo
  35. Tyco

Ask authors/readers for more resources

Objectives We aimed to investigate the long-term prognosis of patients with in-hospital major bleeding (IHMB). Background The effect of IHMB on the long-term prognosis of patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction is unknown. Methods Primary PCI was performed in 3,345 (92.9%) of 3,602 patients in the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial; in-hospital protocol-defined non-coronary artery bypass graft-related major bleeding developed in 231 (6.9%). We examined medication use at discharge, mortality, and major adverse cardiovascular events (composite of death, reinfarction, stroke, or ischemic target vessel revascularization) at 3-year follow-up in patients with and without IHMB. Results At 3-year follow-up, patients with IHMB had higher mortality (24.6% vs. 5.4%, p < 0.0001) and major adverse cardiovascular events (40.3% vs. 20.5%, p < 0.0001). The deleterious effect of major bleeding was observed within 1 month, between 1 month and 1 year, and between 1 and 3 years. IHMB was an independent predictor of mortality (hazard ratio: 2.80; 95% confidence interval: 1.89 to 4.16, p < 0.0001) at 3-year follow up. Conclusions Patients with IHMB after primary PCI have significantly increased 3-year rates of morbidity and mortality. Further investigation is warranted to understand the mechanisms underlying this relationship and to further improve outcomes in patients with ST-segment myocardial infarction. (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI]; NCT00433966) (J Am Coll Cardiol 2011; 58:1750-6) (C) 2011 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Cardiac & Cardiovascular Systems

Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials

Paul Guedeney, Gennaro Giustino, Sabato Sorrentino, Bimmer E. Claessen, Anton Camaj, Deborah N. Kalkman, Birgit Vogel, Samantha Sartori, Salvatore De Rosa, Usman Baber, Ciro Indolfi, Gilles Montalescot, George D. Dangas, Robert S. Rosenson, Stuart J. Pocock, Roxana Mehran

Summary: Treatment with alirocumab or evolocumab is associated with reduced risk of myocardial infarction, stroke, and coronary revascularization, with a favorable safety profile.

EUROPEAN HEART JOURNAL (2022)

Article Cardiac & Cardiovascular Systems

Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from theWIN-TAVIregistry

Johny Nicolas, Bimmer E. Claessen, Davide Cao, Samantha Sartori, Usman Baber, David Power, Mauro Chiarito, Ridhima Goel, Anastasios Roumeliotis, Rishi Chandiramani, Siyan Chen, Jaya Chandrasekhar, Didier Tchetche, Anna Sonia Petronio, Julinda Mehilli, Thierry Lefevre, Patrizia Presbitero, Piera Capranzano, Alessandro Iadanza, Gennaro Sardella, Nicolas M. Van Mieghem, Emanuele Meliga, Nicolas Dumonteil, Chiara Fraccaro, Daniela Trabattoni, Ghada Mikhail, Maria-Cruz Ferrer-Gracia, Christoph Naber, Samin Sharma, Marie-Claude Morice, George D. Dangas, Alaide Chieffo, Roxana Mehran

Summary: Severe anemia in females undergoing TAVI was independently associated with increased rates of VARC-2 efficacy endpoint and mortality at 1 year.

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2021)

Review Cardiac & Cardiovascular Systems

Percutaneous coronary intervention versus medical therapy for chronic total coronary occlusions: a systematic review and meta-analysis of randomised trials

A. van Veelen, J. Elias, I. M. van Dongen, L. P. C. Hoebers, B. E. P. M. Claessen, J. P. S. Henriques

Summary: This meta-analysis of 1790 CTO patients found that CTO-PCI did not lead to improvements in survival or MACE at up to 4 years of follow-up, nor did it improve left ventricular function. However, CTO-PCI resulted in less angina and fewer target lesion revascularisations compared to OMT.

NETHERLANDS HEART JOURNAL (2021)

Review Cardiac & Cardiovascular Systems

Considerations for Optimal Device Selection in Transcatheter Aortic Valve Replacement A Review

Bimmer E. Claessen, Gilbert H. L. Tang, Annapoorna S. Kini, Samin K. Sharma

Summary: Aortic valve stenosis is the most common manifestation of acquired valvular heart disease in developed countries, and transcatheter aortic valve replacement (TAVR) has been established as a safe and effective alternative to surgical aortic valve replacement. Currently, there are only a few TAVR devices commercially available in the US, with several others undergoing clinical trials. Each type of TAVR device has specific strengths and limitations due to differences in engineering features.

JAMA CARDIOLOGY (2021)

Review Cardiac & Cardiovascular Systems

Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey

Davide Cao, Rishi Chandiramani, Mauro Chiarito, Bimmer E. Claessen, Roxana Mehran

Summary: Since its introduction in 1977, percutaneous coronary intervention has become one of the most commonly performed therapeutic procedures worldwide, with antithrombotic agents playing a crucial role in patient management. The past 40 years have seen significant advancements in interventional cardiology in both drug therapies and device technologies.

EUROPEAN HEART JOURNAL (2021)

Review Cardiac & Cardiovascular Systems

Radial versus femoral access for coronary interventions: An updated systematic review and meta-analysis of randomized trials

Mauro Chiarito, Davide Cao, Johny Nicolas, Anastasios Roumeliotis, David Power, Rishi Chandiramani, Samantha Sartori, Anton Camaj, Ridhima Goel, Bimmer E. Claessen, Giulio G. Stefanini, Roxana Mehran, George Dangas

Summary: Radial access for coronary angiography and PCI is associated with a significant reduction in major bleeding, vascular complications, and mortality compared to femoral access, regardless of clinical characteristics. Risk of stroke or MI is comparable between radial and femoral access patients.

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2021)

Article Cardiac & Cardiovascular Systems

Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications

Felix Mahfoud, Michael Weber, Roland E. Schmieder, Melvin D. Lobo, Peter J. Blankestijn, Alexandre Persu, Tim A. Fischell, Helen Parise, Atul Pathak, David E. Kandzari

Summary: The TARGET BP trials are large-scale, international, randomized trials aimed at investigating the safety and efficacy of alcohol-mediated RDN for treating uncontrolled hypertension. The trials have completed enrollment for one cohort and will continue to enroll more subjects in another cohort to evaluate the novel RDN method.

AMERICAN HEART JOURNAL (2021)

Article Cardiac & Cardiovascular Systems

Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris

Anton Camaj, Gennaro Giustino, Nikola Kocovic, Davide Cao, Bimmer E. Claessen, Samantha Sartori, Zhongjie Zhang, Hanbo Qiu, Johny Nicolas, Tomoya Hinohara, Usman Baber, David A. Power, Nitin Barman, Joseph Sweeny, George Dangas, Annapoorna Kini, Samin K. Sharma, Roxana Mehran

Summary: In patients who underwent percutaneous coronary intervention (PCI), elevated levels of high sensitivity C-reactive protein (hsCRP) are associated with an increased risk of ischemic events, regardless of the complexity of the procedure.

AMERICAN JOURNAL OF CARDIOLOGY (2022)

Review Cardiac & Cardiovascular Systems

Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization

Frans J. Beerkens, Bimmer E. Claessen, Marielle Mahan, Mario F. L. Gaudino, Derrick Y. Tam, Jose P. S. Henriques, Roxana Mehran, George D. Dangas

Summary: In this review, the authors explore changes in CABG surgical techniques, differences in conduit pathophysiology, and the latest evidence regarding PCI in patients with previous CABG surgery, focusing on safety and long-term efficacy. They discuss the complexities of contemporary CABG surgery and subsequent percutaneous revascularization in this unique patient population.

NATURE REVIEWS CARDIOLOGY (2022)

Article Cardiac & Cardiovascular Systems

Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial

Shqipdona Lahu, Gjin Ndrepepa, Franz-Josef Neumann, Maurizio Menichelli, Isabell Bernlochner, Gert Richardt, Jochen Wohrle, Bernhard Witzenbichler, Rayyan Hemetsberger, Katharina Mayer, Ibrahim Akin, Salvatore Cassese, Senta Gewalt, Erion Xhepa, Sebastian Kufner, Christian Valina, Hendrik B. Sager, Michael Joner, Tareq Ibrahim, Karl-Ludwig Laugwitz, Heribert Schunkert, Stefanie Schupke, Adnan Kastrati

Summary: Pre-admission treatment with aspirin and/or clopidogrel does not affect the efficacy and safety of ticagrelor and prasugrel in patients with acute coronary syndromes.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

Article Cardiac & Cardiovascular Systems

Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy

Yaling Han, Bimmer E. Claessen, Shao-Liang Chen, Qiu Chunguang, Yujie Zhou, Yawei Xu, Lin Hailong, Jiyan Chen, Wu Qiang, Ruiyan Zhang, Suxin Luo, Yongjun Li, Jianhua Zhu, Xianxian Zhao, Xiang Cheng, Jian'an Wang, Xi Su, Jianhong Tao, Yingxian Sun, Geng Wang, Yi Li, Liya Bian, Ridhima Goel, Samantha Sartori, Zhongjie Zhang, Dominick J. Angiolillo, David J. Cohen, C. Michael Gibson, Adnan Kastrati, Mitchell Krucoff, Shamir R. Mehta, E. Magnus Ohman, Philippe Gabriel Steg, Yuqi Liu, George Dangas, Samin Sharma, Usman Baber, Roxana Mehran

Summary: The TWILIGHT trial enrolled 1169 patients from China, showing that ticagrelor monotherapy significantly reduced clinically relevant bleeding without increasing ischemic events compared to ticagrelor plus aspirin in Chinese patients undergoing high-risk percutaneous coronary intervention.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2022)

Article Cardiac & Cardiovascular Systems

Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk

Shqipdona Lahu, Antonia Presch, Gjin Ndrepepa, Maurizio Menichelli, Christian Valina, Rayyan Hemetsberger, Bernhard Witzenbichler, Isabell Bernlochner, Michael Joner, Erion Xhepa, Alexander Hapfelmeier, Sebastian Kufner, Nonglag Rifatov, Hendrik B. Sager, Katharina Mayer, Thorsten Kessler, Karl-Ludwig Laugwitz, Gert Richardt, Heribert Schunkert, Franz-Josef Neumann, Dirk Sibbing, Dominick J. Angiolillo, Adnan Kastrati, Salvatore Cassese

Summary: This study aimed to compare the efficacy and safety of ticagrelor and prasugrel in acute coronary syndrome patients with high bleeding risk undergoing percutaneous coronary intervention. The results showed that HBR status increased the risk of ischemic and bleeding events in these patients, but there was no significant difference in the treatment effect between ticagrelor and prasugrel. Further studies are needed for confirmation.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2022)

Article Cardiac & Cardiovascular Systems

Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes - A Post-hoc Analysis of the ISAR-REACT 5 Trial

Shqipdona Lahu, Maria Scalamogna, Gjin Ndrepepa, Maurizio Menichelli, Christian Valina, Rayyan Hemetsberger, Bernhard Witzenbichler, Isabell Bernlochner, Michael Joner, Erion Xhepa, Alexander Hapfelmeier, Sebastian Kufner, Hendrik B. Sager, Katharina Mayer, Thorsten Kessler, Karl-Ludwig Laugwitz, Gert Richardt, Heribert Schunkert, Franz-Josef Neumann, Adnan Kastrati, Salvatore Cassese

Summary: This study compares the efficacy and safety of ticagrelor and prasugrel in patients with acute coronary syndrome and prior myocardial infarction (MI). The results show that prasugrel is superior to ticagrelor in reducing the risk of recurrent ischemic events without increasing the risk of bleeding.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

Article Cardiac & Cardiovascular Systems

On-Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two-Year Results From ADAPT-DES

Bahira Shahim, Bjorn Redfors, Thomas D. Stuckey, Mengdan Liu, Zhipeng Zhou, Bernhard Witzenbichler, Giora Weisz, Michael J. Rinaldi, Franz-Josef Neumann, D. Christopher Metzger, Timothy D. Henry, David A. Cox, Peter L. Duffy, Bruce R. Brodie, Iva Srdanovic, Mahesh Madhavan, Ernest L. Mazzaferri, Roxana Mehran, Ori Ben-Yehuda, Ajay J. Kirtane, Gregg W. Stone

Summary: Diabetes mellitus and high platelet reactivity (HPR) are both associated with increased risk of ischemic events after percutaneous coronary intervention. However, it is unknown whether the HPR-related risk of adverse ischemic events differs according to diabetes mellitus status.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Editorial Material Cardiac & Cardiovascular Systems

Worsening Renal Function After Acute Myocardial Infarction: A Bad Omen?

Niels M. R. van der Sangen, Bimmer E. P. M. Claessen

AMERICAN JOURNAL OF CARDIOLOGY (2023)

No Data Available